ライフサイエンスコーパス: carcinoid tumor

1 months for pancreatic NETs v 7.3 months for carcinoid tumors).

2 months for pancreatic NETs v 18.8 months for carcinoid tumors).

3 s, 33% among pheochromocytomas, and 7% among carcinoid tumors).

4 en ovale; 1 of these also had a primary lung carcinoid tumor.

5 trophic gastritis and multiple large gastric carcinoid tumors.

6 e stomach that were determined to be mucosal carcinoid tumors.

7 all loci tested in both typical and atypical carcinoid tumors.

8 otreotide to treat symptomatic patients with carcinoid tumors.

9 le development of various cancers, including carcinoid tumors.

10 ong patients with metastatic or unresectable carcinoid tumors.

11 ctive in pancreatic endocrine tumors than in carcinoid tumors.

12 eans for diagnosis of primary and metastatic carcinoid tumors.

13 ent of adverse effects caused by products of carcinoid tumors.

14 d to be an option for selected patients with carcinoid tumors.

15 , A2, and A3Rs were present in BON cells and carcinoid tumors.

16 ents (4 male, 4 female) with primary hepatic carcinoid tumors.

17 has been commonly observed in patients with carcinoid tumors.

18 ease stabilization in patients with advanced carcinoid tumors.

19 s of tumorlets from intramucosal spread from carcinoid tumors.

20 like cells and to the development of gastric carcinoid tumors.

21 ssion is useful in the assessment of gastric carcinoid tumors.

22 nts who had undergone resection of bronchial carcinoid tumors.

23 We studied 16 carcinoid tumors, 11 PETs, and 22 associated normal muco

24 ction in paired normal and tumor DNA from 17 carcinoid tumors, 5 SCLCs, and 38 NSCLCs to determine th

25 With the exception of a carcinoid tumor and a necrotic squamous cell carcinoma,

26 ed metastatic neuroendocrine tumors (20 with carcinoid tumors and 11 with other tumors) treated with

27 including 15 of 16 (94%) cases of multifocal carcinoid tumors and 7 of 8 (88%) cases of multifocal pa

28 trointestinal carcinoids comprise 90% of all carcinoid tumors and all carcinoids have malignant poten

29 nts with small tumors, as well as those with carcinoid tumors and bronchioloalveolar cell carcinoma,

30 More patients with carcinoid tumors and carcinoid syndrome are requiring an

31 patients were studied: subjects with typical carcinoid tumors and coexisting tumorlets (n = 5), typic

32 ur cases, including 16 multifocal intestinal carcinoid tumors and eight multifocal pancreatic endocri

33 e investigated whether multifocal intestinal carcinoid tumors and multifocal pancreatic endocrine tum

34 Carcinoid tumors and pancreatic endocrine tumors (PETs)

35 he aim of this study was to evaluate CIMP in carcinoid tumors and PETs.

36 ference in chromosome 3p alterations between carcinoid tumors and SCLCs favors a stochastic rather th

37 of neuroendocrine tumors (five patients with carcinoid tumors and three patients with islet cell tumo

38 In patients having both carcinoid tumors and tumorlets, the latter showed alleli

39 All patients had metastatic carcinoid tumors and were on somatostatin analog.

40 an increased risk of gastric polyps, gastric carcinoid tumors, and possibly adenocarcinomas.

41 ighly up-regulated in human gastrointestinal carcinoid tumors, and we sought to define its pathogenic

42 gnetic resonance imaging, metastatic orbital carcinoid tumors appear as nonspecific tumor masses.

43 Gastric carcinoid tumors are rare lesions but have been the focu

44 Carcinoid tumors arise from Kulchitsky cells that origin

45 Carcinoid tumors arise from neuroendocrine cells and may

46 ts as an initial examination for the primary carcinoid tumor as well as for metastases.

47 described significant prognostic features of carcinoid tumors as site of origin, age, sex, stage at d

48 ctive analysis of 150 patients with GI tract carcinoid tumors at the Massachusetts General Hospital w

49 ell lines as models for small intestinal or 'carcinoid' tumor biology are considered appropriate.

50 l deaths (1 was not related to the patient's carcinoid tumor but was due to a second coexistent cance

51 RNA is low to undetectable in human SCLC and carcinoid tumors, but the HGFL/MSP tyrosine kinase recep

52 vasoactive substances into the circulation, carcinoid tumors can cause right-sided valvular heart di

53 Carcinoid tumors can now be localized with 111In octreot

54 etion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel an

55 The radiographic responses in patients with carcinoid tumors comprised a minor response in 2 patient

56 matic responses in patients with functioning carcinoid tumors comprised complete resolution in 3 of t

57 neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in

58 study indicates that methylation profile of carcinoid tumors differs from PETs, reflecting different

59 ed for more aggressive surgical treatment of carcinoid tumors, especially in the setting of hepatic m

60 imbalance was significantly associated with carcinoid tumor formation (P < 0.01).

61 imbalance was shown to be an early event in carcinoid tumor formation by virtue of the absence of al

62 ation of surgery increased significantly for carcinoid tumors from 78.8% to 87.4% (P < 0.0001).

63 hree patients with small, solitary, indolent carcinoid tumors had false-negative results.

64 Surgically treated patients with carcinoid tumor have an overall favorable 83% 5-year sur

65 Gastrointestinal tract carcinoid tumors have a nonspecific clinical presentatio

66 Carcinoid tumors have an affinity for uptake of the radi

67 dy demonstrates that (1) incidence rates for carcinoid tumors have changed, (2) the most common gastr

68 Carcinoid tumors have high numbers of somatostatin recep

69 The overall incidence rates for carcinoid tumors have increased significantly over the p

70 graphic (echo) characteristics of metastatic carcinoid tumor in the heart.

71 w evidence with respect to the prevalence of carcinoid tumors in the middle and right lower lobe, wit

72 that characteristically are up-regulated in carcinoid tumors, including neurotensin and connective t

73 he current biologic understanding of gastric carcinoid tumors, including the role of hypergastrinemia

74 From 1973 to 2004, the incidence of carcinoid tumors increased more than 4-fold (2.1 to 9.3

75 derstanding of the biologic basis of gastric carcinoid tumors increases, the treatment will likely be

76 Features of patients with metastatic carcinoid tumor involving the heart (MCH) have not been

77 in patients with small bowel neuroendocrine (carcinoid) tumors, irrespective of symptom status.

78 The incidence of carcinoid tumors is much greater than previously recogni

79 cal arenas, the optimal treatment of gastric carcinoid tumors is still a matter of debate.

80 Patients with stage IV carcinoid tumors may benefit from more aggressive surgic

81 We present a case of metastatic carcinoid tumor metastatic to the heart, presenting as v

82 Gastric carcinoid tumors occurred as a consequence of chronic hy

83 Multicentric carcinoid tumors occurred in 15 patients (10%), and all

84 ted in patients with a patent foramen ovale, carcinoid tumor of the lung, and active carcinoid syndro

85 They can be subdivided into the carcinoid tumors of the gastrointestinal submucosa and t

86 Carcinoid tumors of the liver are rare and pose a diagno

87 adenocarcinoma, squamous cell carcinoma, and carcinoid tumors of the lung.

88 ears of follow-up, 60 adenocarcinomas and 80 carcinoid tumors of the small intestine were diagnosed.

89 trast, we noted a markedly elevated risk for carcinoid tumors of the small intestine with saturated f

90 sed meat intake and either adenocarcinoma or carcinoid tumors of the small intestine.

91 Carcinoid tumors often present with metastatic disease.

92 n correlated with methylation of p16 gene in carcinoid tumors (p = 0.006).

93 The molecular alterations that underlie carcinoid tumor pathogenesis remain poorly defined.

94 Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemot

95 a (NSCLC), the extent of such abnormality in carcinoid tumors remained to be investigated.

96 Carcinoid tumors secrete many different types of substan

97 thyroid tumors, one gastrinoma, and one lung carcinoid tumor) showed allelic loss that placed the MEN

98 enrolled in the Natural History of Familial Carcinoid Tumor study at the National Institutes of Heal

99 Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, p = 0.

100 tment outcome was analyzed for patients with carcinoid tumors (the most common tumors in this study),

101 st to the relatively conserved karyotypes of carcinoid tumors, the karyotypes of SCLC tumors and cell

102 Of carcinoid tumors, those arising from a midgut location h

103 d chromogranin A messenger RNA abundance, in carcinoid tumor tissue and macroscopically normal corpus

104 uptake of 131I-MIBG indicative of metastatic carcinoid tumor to the orbit.

105 It is rare for carcinoid tumors to metastasize to the eye or to the orb

106 For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies h

107 The primary carcinoid tumor was in the small bowel in 83% of patient

108 One myocardial metastatic carcinoid tumor was removed.

109 The median overall survival in patients with carcinoid tumors was 47 mo (95% confidence interval, 32-

110 xtracted from archival tissue sections of 35 carcinoid tumors was assessed for LOH with eight polymor

111 ranscript and protein levels indicative of a carcinoid tumor were identified in one acute appendiciti

112 ad undergone complete resection of bronchial carcinoid tumors were associated with increased local-re

113 Carcinoid tumors were frequently methylated at RARbeta,

114 wo hundred forty-nine patients with advanced carcinoid tumors were randomized to either doxorubicin w

115 with advanced pancreatic endocrine tumors or carcinoid tumors were treated with rhEndostatin administ

116 increased considerably, primarily because of carcinoid tumors which are now the most common small bow

117 We report a case of a patient with a known carcinoid tumor who developed a left orbital mass that d

118 es permit identification and localization of carcinoid tumors with greater accuracy.

119 luramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT(2A)

120 similar to those of two samples of pulmonary carcinoid tumors, with an average correlation coefficien

121 agnosis, management, and treatment of rectal carcinoid tumors, with special emphasis on minimally inv

122 reatic NETs (33%; five of 15) and those with carcinoid tumors (zero of 19).